Bronchial asthma
Conditions
Interventions
The patients of intervention group are treated their bronchial asthma attack with HFNC therapy and short acting beta 2 stimulate agonist nebulizer four times a day.
The patients of control group are
Sponsors
Department of pediatrics, Showa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patient of bronchial asthma who is modified pulmonary index score 9 or more after administration of methylprednisolone 1 mg/kg and short acting beta 2 stimulate agonist nebulizer of two times or more within two hours prior to study initiation
Exclusion criteria
Exclusion criteria: The patients who cannot be obtained informed consent by themselves or their guardians. There is respiratory failure, shock, or disturbance of consciousness which requires mechanical ventilation. The patients with chronic lung disease, cyanotic heart disease, systemic disease that can exhibit wheezing, a history of arrhythmia provoked by beta 2 stimulate agonist, croup syndrome, suspicious of aspiration of foreign body, bronchiolitis, lobar atelectasis, pneumomediastinum, subcutaneous emphysema. The patient who the attending physician determines inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Variation from the baseline value of modified pulmonary index score three hours after the start of treatments | — |
Countries
Japan
Contacts
Public ContactToshinori Nakamura
Showa University Department of pediatrics
Outcome results
None listed